Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

NCT02104739 · Completed

Last updated 2026-05-28

This clinical trial tests how different diabetes medications affect immune cell activity in people with prediabetes and obesity after eating a meal.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 21 people

Who can join Ages 30–70 · all sexes Healthy volunteers accepted.

Timeline Started 2014-04 · est. completion 2017-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02104739 ↗

Description as written by the study sponsor.

This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk. Newer anti-diabetic agents - exenatide and saxagliptin - impact lipid metabolism. These medications will be studied for their effect in reducing both postprandial lipid levels and arterial dysfunction.

Treatments tested

Exenatide also known as Byetta Drug

Single subcutaneous injection (10 mcg)
Saxagliptin also known as Onglyza Drug

Single dose orally (5 mg)
Exenatide extended-release (ER) also known as Bydureon Drug

Subcutaneous injection (2mg) weekly for 6 weeks
Placebo Other

Placebo tablets and Placebo (normal saline) injections

Main thing measured	Monocyte NfkB Levels as Detected by Western Blotting
Sponsor	The University of Texas Health Science Center, Houston
Conditions studied	Prediabetes, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02104739 ↗